



<b>Form PTO-1449 (Substitute) U.S. Department of Commerce Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/646,070
	<b>Filing Date</b>	August 22, 2003
	<b>First Named Inventor</b>	Michael Wayne Graham
	<b>Art Unit</b>	1635
	<b>Examiner Name</b>	Whiteman, B.
	<b>Attorney Docket No.</b>	0687/74768-BA-PCT-US/JPW/GJG/MJP

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Third party observations under article 115 EPC against European Patent Application EP 98964202.0 in the name of Carnegie Institution of Washington, submitted to the European Patent Office on March 24, 2009;	
	2	Amendment submitted May 11, 2009 in connection with U.S. Serial No. 11/179,504, filed July 13, 2005;	
	3	Communication issued May 21, 2009 in connection with U.S. Serial No. 11/218,999, filed September 2, 2005;	
	4	Response to Communication submitted June 22, 2009 in connection with U.S. Serial No. 11/218,999, filed September 2, 2005;	
	5	Office Action issued May 11, 2009 in connection with U.S. Serial No. 09/287,632, filed April 7, 1999;	
	6	Office Action issued May 12, 2009 in connection with U.S. Serial No. 11/607,062, filed December 1, 2006;	
	7	Restriction Requirement issued May 4, 2009 in connection with U.S. Serial No. 11/841,737, filed August 20, 2007;	
	8	Giering J.C., et al. (2008) "Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic," Mol Ther. 16(9):1630-6;	
	9	Ruiz F, Vayssié L, Klotz C, Sperling L, Madeddu L. (1998) "Homology-dependent gene silencing in Paramecium," Mol Biol Cell. 9(4):931-43;	
	10	Sánchez Alvarado A, Newmark PA. (1999) "Double-stranded RNA specifically disrupts gene expression during planarian regeneration," Proc Natl Acad Sci U S A. 96(9):5049-54; and	
	11	Song J., et al. (2004) "Poly(U) and polyadenylation termination signals are interchangeable for terminating the expression of shRNA from a pol II promoter," Biochem Biophys Res Commun. 323(2):573-8.	

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
---------------------------	------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

# **EXHIBIT B**

**Supplemental Information Disclosure Statement**

Submitted: July 15, 2009

**Serial No. 10/646,070**

Filed: April 22, 2003

Applicants: Michael Wayne Graham et al.

Exhibit B: Table of Locations for Disclosed Documents

Document	Document Description	Document Location
1	Third party observations under article 115 EPC against European Patent Application EP 98964202.0 in the name of Carnegie Institution of Washington, submitted to the European Patent Office on March 24, 2009;	Attached hereto as Exhibit C
2	Amendment submitted May 11, 2009 in connection with U.S. Serial No. 11/179,504, filed July 13, 2005;	Submitted May 11, 2009 in connection with U.S. Serial No. 11/179,504, filed July 13, 2005
3	Communication issued May 21, 2009 in connection with U.S. Serial No. 11/218,999, filed September 2, 2005;	Issued May 21, 2009 in connection with U.S. Serial No. 11/218,999, filed September 2, 2005
4	Response to Communication submitted June 22, 2009 in connection with U.S. Serial No. 11/218,999, filed September 2, 2005;	Submitted June 22, 2009 in connection with U.S. Serial No. 11/218,999, filed September 2, 2005
5	Office Action issued May 11, 2009 in connection with U.S. Serial No. 09/287,632, filed April 7, 1999;	Issued May 11, 2009 in connection with U.S. Serial No. 09/287,632, filed April 7, 1999
6	Office Action issued May 12, 2009 in connection with U.S. Serial No. 11/607,062, filed December 1, 2006;	Issued May 12, 2009 in connection with U.S. Serial No. 11/607,062, filed December 1, 2006
7	Restriction Requirement issued May 4, 2009 in connection with U.S. Serial No. 11/841,737, filed August 20, 2007;	Issued May 4, 2009 in connection with U.S. Serial No. 11/841,737, filed August 20, 2007

Document	Document Description	Document Location
8	Giering J.C., et al. (2008) "Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic," Mol Ther. 16(9):1630-6;	Submitted May 11, 2009 with an Information Disclosure Statement in connection with U.S. Serial No. 11/179,504, filed July 13, 2005
9	Ruiz F, Vayssié L, Klotz C, Sperling L, Madeddu L. (1998) "Homology-dependent gene silencing in Paramecium," Mol Biol Cell. 9(4):931-43;	Submitted May 11, 2009 with an Information Disclosure Statement in connection with U.S. Serial No. 11/179,504, filed July 13, 2005
10	Sánchez Alvarado A, Newmark PA. (1999) "Double-stranded RNA specifically disrupts gene expression during planarian regeneration," Proc Natl Acad Sci U S A. 96(9):5049-54; and	Submitted May 11, 2009 with an Information Disclosure Statement in connection with U.S. Serial No. 11/179,504, filed July 13, 2005
11	Song J., et al. (2004) "Poly(U) and polyadenylation termination signals are interchangeable for terminating the expression of shRNA from a pol II promoter," Biochem Biophys Res Commun. 323(2):573-8.	Submitted May 11, 2009 with an Information Disclosure Statement in connection with U.S. Serial No. 11/179,504, filed July 13, 2005